Oncotarget

Research Papers:

Assessing the clinical utility of genomic expression data across human cancers

Xinsen Xu _, Lei Huang, Chun Hei Chan, Tao Yu, Runchen Miao and Chang Liu

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:45926-45936. https://doi.org/10.18632/oncotarget.10002

Metrics: PDF 971 views  |   HTML 1699 views  |   ?  


Abstract

Xinsen Xu1, Lei Huang2, Chun Hei Chan3, Tao Yu4, Runchen Miao1, Chang Liu1

1Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

2118 Lancaster Terrace, Brookline, MA, USA

3Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong

4Department of Neurosurgery, Peking University First Hospital, Beijing, China

Correspondence to:

Chang Liu, email: liuchangdoctor@163.com

Keywords: genome, cancer, expression, utility, prognosis

Received: February 24, 2016    Accepted: May 29, 2016    Published: June 14, 2016

ABSTRACT

Cancer molecular profiling provides better understanding of tumor mechanisms and helps to improve the existing cancer management. Here we present the gene expression signatures from ~9000 human tumors with clinical information across 32 malignancies from The Cancer Genome Atlas project (TCGA). Major predictors from the RNA sequencing data that were significantly correlated with cancer survival were identified. The expression level of these prognostic genes revealed significant genomic pathways that were clinically relevant to survival outcomes across human cancers. Furthermore, it is shown that in most cancer types, combinations of these genomic signatures with clinical information might yield improved predictions. Thus, with respect to clinical utility, our study reveals the promising values of genomic data from the pan-cancer perspective.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10002